Skip to main content

NCI Funding for HIV and AIDS Malignancies Research

Current NCI Funding Opportunities in HIV/AIDS and AIDS Malignancies are listed below.

Implementation Science for Cancer 
Control in People Living with HIV in 
Low- and Middle-Income Countries 

The purpose of these Funding Opportunity Announcement is 
to support  Implementation Science for Cancer Control in People 
Living with HIV (PLWH) in Low- and Middle-Income Countries 
(LMICs) to accelerate the integration of evidence-based cancer 
control interventions for PLWH by leveraging existing HIV treatment 
and prevention infrastructure. Responsive applications should include 
multi-disciplinary teams of researchers with expertise in HIV, cancer, 
and implementation science to address the cancer control needs of 
PLWH populations specific to the LMIC.

Additional Information:
Implementation Science for Cancer Control in People Living with HIV 
in Low- and Middle-Income Countries (U01 Clinical Trial Optional)


Understanding Oral Human Papilloma Virus (HPV) Infection, 
Acquisition, and Persistence in People Living with HIV (PLWH)

The purpose of these Funding Opportunity Announcements are to better
understand the epidemiology and biology of oral HPV infection, its acquisition
persistence in PLWH and to elucidate the initial mechanisms related to HPV-
associated oral and oropharyngeal cancers and warts in the context of HIV.

Additional Information:
Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, 
and Persistence in People Living with HIV (R01 Clinical Trial Not Allowed)
Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, 
and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed)

The role of Epstein Barr Virus (EBV) infection in Non-
Hodgkin Lymphoma (NHL) and Hodgkin disease (HD)
development with or without an underlying HIV infection 

This funding opportunity announcement (FOA) focuses on the role of EBV infection
on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or 
without an underlying HIV infection. Research project U01s funded through this PAR
will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium
(EALC).

Additional Information:
The role of Epstein Barr Virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and
Hodgkin disease (HD) development with or without an underlying HIV infection
(U01 Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS 
Prevention, Treatment and Care in Low- and Middle-Income
Countries

The goals of this FOA is to solicit R01 applications for up to 3 years of support to develop and 
test interventions to reduce the impact of HIV-associated stigma on the prevention and
treatment of HIV infection and/or AIDS, and the quality of life of People Living with HIV/AIDS
(PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and
measurement of stigmas at individual levels.  For example support intervention research
on strategies to cope with the complex burden of stigmatization due to HIV and one
or more comorbidities/coinfections.

Additional Information:
Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and
Care in Low- and Middle-Income Countries (R01 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at 
Low- and Middle-Income Country Institutions 

The goals of this program are to support locally relevant research in critical  areas of HIV-
associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) 
Institutions, to enhance research capacity,  and to build a network of researchers both within 
and across LMICs to address this critical burden. NCI is interested in research projects aimed 
at identifying specific contributions of HIV infection and its potential interaction with other 
pathogens towards the development and pathogenesis of cancer, or provide information 
on the clinical outcomes in people living with HIV and cancer.

Additional Information:
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country 
Institutions (R21 Clinical Trial Optional)

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health

This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Additional Information:
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global 
Health (U01 Clinical Trial Optional)

Notice of Special Interest (NOSI): Use of Biological "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers

The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. Research efforts that identify specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of these cancers and provide information on the clinical outcomes of such cancers in the HIV-infected population are sought. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

High or medium priority AIDS research as described in NOT-OD-15-137 is encouraged in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV)

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the modes of transmission of KSHV; the biology of the initial steps of infection; and the risk factors of infection. The proposed studies should inform and advance efforts to reduce or eliminate KSHV transmission and prevention of  Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.

Additional Information:
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus 
(KSHV) (R01 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This initiative solicits applications at the intersection of HIV and aging.  NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.

Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

 

  • Updated: